A positron emission tomography (PET) imaging agent could show, ahead of time, whether a specific treatment is likely to be effective for major depressive disorder (MDD)—a debilitating condition that affects more than 14 million Americans. No such marker is currently available in clinical psychiatry. The study is featured in the April issue of The Journal of Nuclear Medicine.  {read more here}